2021 Fiscal Year Final Research Report
Development of therapeutic agent for ulcerative colitis tatrgeting urokinase-type plasminogen activator
| Project/Area Number |
20K16958
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 53010:Gastroenterology-related
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2022-03-31
|
| Keywords | 潰瘍性大腸炎 / ウロキナーゼ型プラスミノーゲンアクチベータ / 血管新生 / RANTES |
|---|
| Outline of Final Research Achievements |
It has reported that abnormal angiogenesis is associated with the etiology of UC. In this study, We investigated mRNA expression of angiogenesis-related factors in colitis tissue of UC patients. uPA was highly expressed in colitis tissue and correlated with endoscopic severity of UC. We also found that uPA inhibition ameliorated DSS-induced colitis in mice. These data indicate that uPA plays an important role in exacerbation of UC, and suggest that uPA may be a potential therapeutic target for the treatment of UC.
|
| Free Research Field |
炎症性腸疾患
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究ではuPAがUC患者の炎症粘膜に浸潤した好中球に発現しており、炎症の程度の相関することを見出した。また、大腸炎マウスモデルにおいて、uPAを阻害することにより大腸炎が軽減され、uPAが大腸炎の増悪因子であることが示唆された。またuPA阻害によりRANTESの有意な低下を認めた。これらの結果からuPAやRANTESが潰瘍性大腸炎の治療標的となる可能性がある。
|
